Prevention of tolerance to stimulant ADHD medication

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted patent US12594250B2 to James Martin Swanson for methods of preventing accumulated tolerance to stimulant medication used in ADHD treatment. The patent discloses pharmaceutical compositions with controlled-release formulations combining immediate-release and sustained-release components to counteract acute tolerance. The patent contains 16 claims covering methods of treatment using ascending delivery profiles.

View original document View source feed page

What changed

USPTO granted patent US12594250B2 for methods of preventing accumulated tolerance to stimulant medication for ADHD treatment. The patent discloses pharmaceutical formulations combining an immediate-release component with a sustained-release component designed to prevent carry-over effects on background tonic dopamine. The filing date was April 10, 2025, with application number 19176038. The patent contains 16 claims covering formulation approaches and methods of treatment.

Pharmaceutical companies developing ADHD medications or generic formulations may need to consider this patent when designing products. The patent holder gains exclusive rights to these specific formulation approaches in the US market through the patent term. Competitors may need to obtain licenses or design around the disclosed methods to avoid infringement.

What to do next

Monitor for patent expiry dates and potential for license negotiations
Review formulation approaches for ADHD medications to assess potential infringement
Consult IP counsel regarding freedom-to-operate analysis for competing products

Source document (simplified)

← USPTO Patent Grants

Prevention of accumulated tolerance to stimulant medication for the treatment of ADHD

Grant US12594250B2 Kind: B2 Apr 07, 2026

Inventors

James Martin Swanson

Abstract

It is proposed that dissipation of relative benefit during long-term treatment is due to long-term tolerance to stimulant medications. To improve adherence and persistence of medication use, it is advantageous to develop medications that are not undermined by long-term tolerance. Disclosed herein in certain implementations are methods for the prevention of accumulated tolerance to stimulant medication for the treatment of ADHD based on two principles: (a) retaining the initial immediate-release component of controlled-release formulations, and (b) replacing the subsequent sustained-release component (i.e., an ascending delivery of stimulant medication to counteract acute tolerance) with a controlled-release component designed to prevent carry-over effects on background tonic dopamine.